vs
INTERNATIONAL BANCSHARES CORP（IBOC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
INTERNATIONAL BANCSHARES CORP的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$217.7M vs $207.3M），INTERNATIONAL BANCSHARES CORP净利率更高（62.3% vs -62.0%，领先124.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 4.5%），INTERNATIONAL BANCSHARES CORP自由现金流更多（$472.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.8%）
国际银行股份公司（International Bancshares Corporation）是总部位于美国得克萨斯州拉雷多的银行控股公司，核心子公司为国际商业银行。目前集团通过旗下银行子公司运营217个营业网点、315台自动柜员机，服务覆盖得克萨斯州、俄克拉荷马州的88个城镇社区。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
IBOC vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $217.7M | $207.3M |
| 净利润 | $106.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 62.8% | -54.7% |
| 净利率 | 62.3% | -62.0% |
| 营收同比 | 4.5% | 25.9% |
| 净利润同比 | -7.1% | 3.5% |
| 每股收益（稀释后） | $1.71 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $217.7M | $207.3M | ||
| Q3 25 | $218.1M | $159.9M | ||
| Q2 25 | $208.2M | $166.5M | ||
| Q1 25 | $198.2M | $139.3M | ||
| Q4 24 | $208.3M | $164.6M | ||
| Q3 24 | $211.8M | $139.5M | ||
| Q2 24 | $207.8M | $147.0M | ||
| Q1 24 | $205.8M | $108.8M |
| Q4 25 | $106.9M | $-128.6M | ||
| Q3 25 | $108.4M | $-180.4M | ||
| Q2 25 | $100.1M | $-115.0M | ||
| Q1 25 | $96.9M | $-151.1M | ||
| Q4 24 | $115.1M | $-133.2M | ||
| Q3 24 | $99.8M | $-133.5M | ||
| Q2 24 | $97.0M | $-131.6M | ||
| Q1 24 | $97.3M | $-170.7M |
| Q4 25 | 62.8% | -54.7% | ||
| Q3 25 | 62.6% | -106.9% | ||
| Q2 25 | 60.5% | -64.8% | ||
| Q1 25 | 61.1% | -102.6% | ||
| Q4 24 | 64.2% | -74.3% | ||
| Q3 24 | 60.0% | -94.6% | ||
| Q2 24 | 60.1% | -79.1% | ||
| Q1 24 | 59.9% | -151.9% |
| Q4 25 | 62.3% | -62.0% | ||
| Q3 25 | 49.7% | -112.8% | ||
| Q2 25 | 48.1% | -69.0% | ||
| Q1 25 | 48.9% | -108.5% | ||
| Q4 24 | 71.5% | -80.9% | ||
| Q3 24 | 47.1% | -95.7% | ||
| Q2 24 | 46.7% | -89.5% | ||
| Q1 24 | 47.3% | -156.8% |
| Q4 25 | $1.71 | $-1.28 | ||
| Q3 25 | $1.74 | $-1.81 | ||
| Q2 25 | $1.61 | $-1.17 | ||
| Q1 25 | $1.56 | $-1.57 | ||
| Q4 24 | $1.85 | $-1.34 | ||
| Q3 24 | $1.60 | $-1.40 | ||
| Q2 24 | $1.56 | $-1.52 | ||
| Q1 24 | $1.56 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.5B | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3B | $-80.0M |
| 总资产 | $16.6B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $5.5B | $421.0M | ||
| Q3 25 | $5.6B | $202.5M | ||
| Q2 25 | $5.8B | $176.3M | ||
| Q1 25 | $5.6B | $127.1M | ||
| Q4 24 | $5.4B | $174.0M | ||
| Q3 24 | $5.8B | $150.6M | ||
| Q2 24 | $5.7B | $480.7M | ||
| Q1 24 | $5.7B | $112.3M |
| Q4 25 | $3.3B | $-80.0M | ||
| Q3 25 | $3.1B | $9.2M | ||
| Q2 25 | $3.0B | $151.3M | ||
| Q1 25 | $2.9B | $144.2M | ||
| Q4 24 | $2.8B | $255.0M | ||
| Q3 24 | $2.7B | $346.8M | ||
| Q2 24 | $2.6B | $432.4M | ||
| Q1 24 | $2.5B | $140.3M |
| Q4 25 | $16.6B | $1.5B | ||
| Q3 25 | $16.6B | $1.2B | ||
| Q2 25 | $16.5B | $1.3B | ||
| Q1 25 | $16.3B | $1.3B | ||
| Q4 24 | $15.7B | $1.5B | ||
| Q3 24 | $15.9B | $1.5B | ||
| Q2 24 | $15.5B | $1.6B | ||
| Q1 24 | $15.4B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $491.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $472.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 217.2% | -48.6% |
| 资本支出强度资本支出/营收 | 8.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.59× | — |
| 过去12个月自由现金流最近4个季度 | $809.9M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $491.1M | $-99.8M | ||
| Q3 25 | $115.2M | $-91.4M | ||
| Q2 25 | $95.5M | $-108.3M | ||
| Q1 25 | $140.5M | $-166.5M | ||
| Q4 24 | $473.9M | $-79.3M | ||
| Q3 24 | $116.5M | $-67.0M | ||
| Q2 24 | $107.2M | $-77.0M | ||
| Q1 24 | $135.4M | $-190.7M |
| Q4 25 | $472.9M | $-100.8M | ||
| Q3 25 | $112.2M | $-92.7M | ||
| Q2 25 | $91.6M | $-110.7M | ||
| Q1 25 | $133.1M | $-167.8M | ||
| Q4 24 | $459.8M | $-79.5M | ||
| Q3 24 | $109.6M | $-68.6M | ||
| Q2 24 | $104.9M | $-79.0M | ||
| Q1 24 | $128.9M | $-193.9M |
| Q4 25 | 217.2% | -48.6% | ||
| Q3 25 | 51.5% | -58.0% | ||
| Q2 25 | 44.0% | -66.5% | ||
| Q1 25 | 67.1% | -120.5% | ||
| Q4 24 | 220.8% | -48.3% | ||
| Q3 24 | 51.7% | -49.2% | ||
| Q2 24 | 50.5% | -53.7% | ||
| Q1 24 | 62.6% | -178.2% |
| Q4 25 | 8.3% | 0.5% | ||
| Q3 25 | 1.3% | 0.8% | ||
| Q2 25 | 1.9% | 1.5% | ||
| Q1 25 | 3.7% | 1.0% | ||
| Q4 24 | 6.8% | 0.1% | ||
| Q3 24 | 3.3% | 1.2% | ||
| Q2 24 | 1.1% | 1.4% | ||
| Q1 24 | 3.2% | 3.0% |
| Q4 25 | 4.59× | — | ||
| Q3 25 | 1.06× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 1.45× | — | ||
| Q4 24 | 4.12× | — | ||
| Q3 24 | 1.17× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 1.39× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBOC
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
